Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;34(6):1006-1007.
doi: 10.1038/s41433-019-0722-6. Epub 2019 Nov 29.

Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect

Ashish Sharma  1 , Nilesh Kumar  2 , Francesco Bandello  3 , Anat Loewenstein  4 , Baruch D Kuppermann  5
Affiliations

Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect

Ashish Sharma et al. Eye (Lond). 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. US FDA. Biological Product Definitions. FDA. https://www.fda.gov/media/108557/download. Accessed 25 Oct 2019.
    1. The Vision Academy Steering Committee. Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259–73. doi: 10.1007/s00417-017-3647-4. - DOI - PMC - PubMed
    1. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019; pii: S0161-6420(18)33018-5. - PubMed
    1. Sharma Ashish, Kumar Nilesh, Kuppermann Baruch D, Loewenstein Anat, Bandello Francesco. Brolucizumab: is extended VEGF suppression on the horizon? Eye. 2019;34(3):424–426. doi: 10.1038/s41433-019-0582-0. - DOI - PMC - PubMed
    1. Sharma Ashish, Kumar Nilesh, Kuppermann Baruch D., Bandello Francesco. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye. 2019;34(5):797–801. doi: 10.1038/s41433-019-0607-8. - DOI - PMC - PubMed

Substances